These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 7495962)

  • 21. A solvent/detergent-treated and 15-nm filtered factor VIII: a new safety standard for plasma-derived coagulation factor concentrates.
    Chtourou S; Porte P; Nogré M; Bihoreau N; Cheesman E; Samor B; Sauger A; Raut S; Mazurier C
    Vox Sang; 2007 May; 92(4):327-37. PubMed ID: 17456157
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An outbreak of hepatitis A among South African patients with hemophilia: evidence implicating contaminated factor VIII concentrate as the source.
    Kedda MA; Kew MC; Cohn RJ; Field SP; Schwyzer R; Song E; Fernandes-Costa F
    Hepatology; 1995 Nov; 22(5):1363-7. PubMed ID: 7590648
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Virology of the hepatitis A epidemic in Italy.
    Purcell RH; Mannucci PM; Gdovin S; Gringeri A; Colombo M; Mele A; Schinaia N; Ciavarella N; Emerson SU
    Vox Sang; 1994; 67 Suppl 4():2-7; discussion 24-6. PubMed ID: 7831866
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dry-heat treatment process for enhancing viral safety of an antihemophilic factor VIII concentrate prepared from human plasma.
    Kim IS; Choi YW; Kang Y; Sung HM; Shin JS
    J Microbiol Biotechnol; 2008 May; 18(5):997-1003. PubMed ID: 18633304
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A solvent I detergent treated, pasteurised and highly purified factor VIII concentrate.
    Schwinn H; Stadler M; Josic D; Bal F; Gehringer W; Nur I; Schütz R
    Arzneimittelforschung; 1994 Feb; 44(2):188-91. PubMed ID: 8147954
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hepatitis A virus prevalence in plasma donations.
    Weimer T; Streichert S; Watson C; Gröner A
    J Med Virol; 2002 Aug; 67(4):469-71. PubMed ID: 12115990
    [No Abstract]   [Full Text] [Related]  

  • 27. A case report of post-transfusion hepatitis A.
    Skidmore SJ; Boxall EH; Ala F
    J Med Virol; 1982; 10(3):223. PubMed ID: 6296315
    [No Abstract]   [Full Text] [Related]  

  • 28. Self-sufficiency and blood transmitted diseases.
    Glomstein A
    Blood Coagul Fibrinolysis; 1995 Jul; 6 Suppl 2():S23-6. PubMed ID: 7495963
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prospective study of the evaluation of hepatitis C virus infectivity in a high-purity, solvent/detergent-treated factor VIII concentrate: parallel evaluation of other markers for lipid-enveloped and non-lipid-enveloped viruses. The Ad Hoc Study Group of the Fondazione dell'Emofilia.
    Mariani G; Di Paolantonio T; Baklaya R; Morfini M; Mannucci PM
    Transfusion; 1993 Oct; 33(10):814-8. PubMed ID: 8236421
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of terminal (dry) heat treatment on non-enveloped viruses in coagulation factor concentrates.
    Hart HF; Hart WG; Crossley J; Perrie AM; Wood DJ; John A; McOmish F
    Vox Sang; 1994; 67(4):345-50. PubMed ID: 7701804
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Non-enveloped viruses transmitted by blood and blood products.
    Robertson BH; Erdman DD
    Dev Biol (Basel); 2000; 102():29-35. PubMed ID: 10794088
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Implementation of a 20-nm pore-size filter in the plasma-derived factor VIII manufacturing process.
    Furuya K; Murai K; Yokoyama T; Maeno H; Takeda Y; Murozuka T; Wakisaka A; Tanifuji M; Tomono T
    Vox Sang; 2006 Aug; 91(2):119-25. PubMed ID: 16907872
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inactivation of hepatitis A virus by pasteurization and elimination of picornaviruses during manufacture of factor VIII concentrate.
    Hilfenhaus J; Nowak T
    Vox Sang; 1994; 67 Suppl 1():62-6. PubMed ID: 8091740
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hepatitis A Virus Transmission by Blood Products. Proceedings of a symposium. New York, 10 July 1993.
    Vox Sang; 1994; 67 Suppl 1():1-86. PubMed ID: 7916516
    [No Abstract]   [Full Text] [Related]  

  • 35. Sequence variability of hepatitis A virus and factor VIII associated hepatitis A infections in hemophilia patients in Europe. An update.
    Robertson BH; Friedberg D; Normann A; Graff J; Flehmig B; Shouval D
    Vox Sang; 1994; 67 Suppl 1():39-45; discussion 46. PubMed ID: 8091736
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Improvement of virus safety of a S/D-treated factor VIII concentrate by additional dry heat treatment at 100 degrees C.
    Dichtelmüller H; Rudnick D; Breuer B; Kotitschke R; Kloft M; Darling A; Watson E; Flehmig B; Lawson S; Frösner G
    Biologicals; 1996 Jun; 24(2):125-30. PubMed ID: 8889059
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Infection with hepatitis G virus among recipients of plasma products.
    Jarvis LM; Davidson F; Hanley JP; Yap PL; Ludlam CA; Simmonds P
    Lancet; 1996 Nov; 348(9038):1352-5. PubMed ID: 8918279
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Investigation of an outbreak of hepatitis A in Irish haemophilia A patients.
    Lawlor E; Johnson Z; Thornton L; Temperley I
    Vox Sang; 1994; 67 Suppl 1():18-9; discussion 20. PubMed ID: 8091729
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Large-scale preparation of a highly purified solvent-detergent treated factor VIII concentrate.
    Myers R; Wickerhauser M; Charamella L; Simon L; Nummy W; Brodniewicz-Proba T
    Vox Sang; 1991; 60(3):141-7. PubMed ID: 1907414
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inactivation and clearance of viruses during the manufacture of high purity factor IX.
    Johnston A; Macgregor A; Borovec S; Hattarki M; Stuckly K; Anderson D; Goss NH; Oates A; Uren E
    Biologicals; 2000 Sep; 28(3):129-36. PubMed ID: 10964439
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.